Department of Otolaryngology-Head and Neck Surgery, Washington University School of Medicine, St. Louis, Missouri, U.S.A.
Division of Public Health Sciences, Department of Surgery, Washington University School of Medicine, St. Louis, Missouri, U.S.A.
Laryngoscope. 2021 Jun;131(6):1310-1319. doi: 10.1002/lary.29260. Epub 2020 Dec 2.
OBJECTIVE/HYPOTHESIS: To assess whether young patients with oral cavity squamous cell carcinoma (OCSCC) demonstrate worse oncologic outcomes than older patients after definitive therapy.
Systematic review and meta-analysis.
A medical librarian composed a search strategy to identify relevant studies in Medline, Embase, Scopus, and other major databases (Prospero registration number CRD42019127974). Inclusion criteria were adults with histologically diagnosed OCSCC that underwent treatment, comparator groups with an age cutoff of 40 years old, and reported survival outcomes. Articles were excluded if they contained patients with oropharyngeal squamous cell carcinoma or patients treated for palliative intent. Overall survival hazard ratios were analyzed with a meta-analysis.
There were 23,382 patients with OCSCC that were treated with definitive therapy from 22 included studies. The pooled cohort contained 2,238 (10%) patients ≤40 years of age. Oral tongue was the most common subsite in both the younger (n = 1,961, 91%) and older (n = 18,047, 88%) cohorts. The majority of OCSCCs were either T1 or T2, representing 859 (80%) malignancies in younger patients and 8,126 (77%) malignancies in older patients. A meta-analysis of nine studies demonstrated that younger patients did not experience worse survival outcomes than older patients (hazard ratio = 0.97, 95% confidence interval = 0.66-1.41).
Young adults with OCSCC experienced similar oncologic outcomes as older patients with OCSCC after definitive treatment. Until compelling evidence demonstrates clinically relevant differences between these two cohorts, their approach to management should be similar. Future studies should consider comorbidities and using age 40 as a standard age cutoff to provide more uniform data moving forward. Laryngoscope, 131:1310-1319, 2021.
目的/假设:评估口腔鳞状细胞癌(OCSCC)的年轻患者在接受确定性治疗后是否比老年患者的肿瘤学结果更差。
系统评价和荟萃分析。
一位医学图书管理员制定了一个搜索策略,以在 Medline、Embase、Scopus 和其他主要数据库(Prospéro 注册号 CRD42019127974)中确定相关研究。纳入标准为接受治疗的组织学诊断为 OCSCC 的成年人、年龄截止为 40 岁的对照组、以及报告的生存结果。如果文章包含口咽鳞状细胞癌患者或姑息治疗患者,则将其排除在外。使用荟萃分析分析总生存风险比。
从 22 项纳入研究中,共有 23382 例接受确定性治疗的 OCSCC 患者。汇总队列包含 2238 名(10%)≤40 岁的患者。年轻患者(n = 1961,91%)和老年患者(n = 18047,88%)中最常见的口腔肿瘤部位是舌。大多数 OCSCC 均为 T1 或 T2,代表年轻患者的 859 种(80%)恶性肿瘤和老年患者的 8126 种(77%)恶性肿瘤。对 9 项研究的荟萃分析表明,年轻患者的生存结果并不比老年患者差(风险比=0.97,95%置信区间=0.66-1.41)。
接受确定性治疗后,OCSCC 的年轻成年患者与 OCSCC 的老年患者具有相似的肿瘤学结果。在有令人信服的证据表明这两个队列之间存在临床相关差异之前,他们的管理方法应该相似。未来的研究应考虑合并症,并使用 40 岁作为标准年龄截止值,以提供更一致的数据。《喉镜》,131:1310-1319,2021。